Critical Care Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Albumin, Prothrombin complex concentrates, Antithrombin concentrates, Factor XIII concentrates, Fibrinogen concentrates), By Application (Deep vein thrombosis, Pulmonary embolism (PE), Acute coronary syndrome, Atrial fibrillation, Hemodialysis, Coronary angioplasty, Surgeries), and Region

Critical Care Therapeutics Market size was valued at US$ 3,492.1 million in 2023 and is expected to grow at a CAGR of 3.1% from 2024 to 2030. Critical care medicine is concerned with the diagnosis and treatment of life-threatening illnesses or injuries such as shock, burns, accidents, complex procedures, sepsis, and severe respiratory issues. It generally takes place in an intensive care unit or a trauma center. The increased incidence of potentially fatal disorders such as cardiovascular disease, and pulmonary disease, the Growing geriatric population, increased awareness, and acceptance of critical organ tests among patients, and technological advances are some of the main drivers expected to fuel market growth over the forecast period.

According to the National Institute of Health (NIH), over 8.5% of people globally are aged 65 and over in 2016, with this figure expected to rise to more than 17% by 2050. Moreover, the increase in surgical operations will also help the expansion of the critical care therapeutics market. The rising number of surgical operations, including hip and knee replacements, will raise the risk of DVT, propelling the industry forward. People who have had knee or hip replacement surgery are more likely to develop DVT. It has also been noted that cases of joint replacements and cardiovascular treatments are more prevalent in the senior population. The growing number of surgical operations may increase the likelihood of having thromboembolic events following surgery, necessitating anticoagulant medication.

Critical Care Therapeutics Market Key Developments:

• July 2021: A team of researchers from the Second Medical Center of the Chinese PLA General Hospital in China undertook a study to assess the impact of dual targeting of PI3K and MEK on human EGFR-TKI resistant NSCLC cell lines. They discovered that this dual method can limit the growth of lung cancer cell lines in persons with varied genetic origins.